Brought to you by 
Amgen buys Ilypsa for $420mm in cash
Jun 2007
Executive Summary
Amgen has acquired Ilypsa (non-absorbed therapeutics for renal disorders) for $420mm in cash. Ilypsa will now become a wholly owned subsidiary of Amgen.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Acquisition of Private Biotech
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen buys Ilypsa for $420mm in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice